Review
Chemistry, Multidisciplinary
Jiao-jiao Ni, Zi-zhen Zhang, Ming-jie Ge, Jing-yu Chen, Wei Zhuo
Summary: As a breakthrough strategy for cancer treatment, immunotherapy stimulates the immune system to fight cancer, providing a durable antitumor response. Due to the low response rate and unique toxicity profiles of immunotherapy, combining it with other therapies has gained attention. Immune-based combination therapy has achieved promising results in clinical trials, with FDA approval for certain cancers.
ACTA PHARMACOLOGICA SINICA
(2023)
Review
Medicine, Research & Experimental
Yuan-Tong Liu, Zhi-Jun Sun
Summary: Immunotherapy, particularly through immune checkpoint inhibitors, has significantly improved the treatment of malignant tumors by enhancing T cell infiltration into tumors. Understanding the mechanisms underlying cold tumors, which lack T cell infiltration, is crucial to improving immunotherapy efficacy. Strategies to transform cold tumors into hot tumors and increase T cell infiltration are discussed, along with the potential of nanomedicines in enhancing tumor immunotherapy.
Article
Pharmacology & Pharmacy
Xiaoqing Liu, Shuang Liang, Xiao Sang, Lili Chang, Shunli Fu, Han Yang, Huizhen Yang, Yongjun Liu, Na Zhang
Summary: In this study, an on-demand integrated nano-engager was developed to convert cold tumors to hot by increasing DNA damage and dual immune checkpoint inhibition strategy, showing significant anti-tumor and anti-metastasis effects.
ACTA PHARMACEUTICA SINICA B
(2023)
Article
Immunology
Guixiu Xiao, Yujie Zhao, Xueyan Wang, Chuan Zeng, Feng Luo, Jing Jing
Summary: This study combines nanoparticle-mediated photothermal therapy (PTT) with anti-PD-1 immunotherapy, offering a potential strategy to convert immune cold tumors into hot ones.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Anna D. Staniszewska, Joshua Armenia, Matthew King, Chrysiis Michaloglou, Avinash Reddy, Maneesh Singh, Maryann San Martin, Laura Prickett, Zena Wilson, Theresa Proia, Deanna Russell, Morgan Thomas, Oona Delpuech, Mark J. O'Connor, Elisabetta Leo, Helen Angell, Viia Valge-Archer
Summary: PARP inhibitors are synthetically lethal with BRCA1/2 mutations and can induce increased DNA damage, leading to cell death. Combination treatment of olaparib and immune checkpoint blockade (ICB) demonstrates durable and deeper anti-tumor activity compared to monotherapies. This combination also modulates the immune microenvironment, enhancing immune response against tumors.
Review
Biochemistry & Molecular Biology
Anna Kuzevanova, Natalya Apanovich, Danzan Mansorunov, Alexandra Korotaeva, Alexander Karpukhin
Summary: Certain problems have been identified in cancer immunotherapy using the inhibition of immune checkpoints (ICs). Additional receptors and ligands as targets for immunotherapy are being explored. In this study, the potential of TIM-3, LAG-3, TIGIT, VISTA, and BTLA receptors as targets for anticancer therapy is comprehensively analyzed. LAG-3 inhibition shows the most effective antitumor response, while TIGIT and BTLA demonstrate promise as targets for anticancer therapy. However, the relationship between VISTA and TIM-3 expression and tumor characteristics is contradictory and inconsistent results are found regarding their antitumor effectiveness.
Review
Pharmacology & Pharmacy
Nathaniel Sheng Hua Too, Nicholas Ching Wei Ho, Christabella Adine, N. Gopalakrishna Iyer, Eliza Li Shan Fong
Summary: This review discusses the parameters that influence the induction of different immune contextures within tumors and how engineering strategies can be utilized to develop the next generation of immune-competent patient-derived in vitro models.
ADVANCED DRUG DELIVERY REVIEWS
(2021)
Article
Nanoscience & Nanotechnology
Qingle Song, Guofang Zhang, Bo Wang, Guoli Cao, Dongjie Li, Yu Wang, Yuqian Zhang, Jin Geng, Hongchang Li, Yang Li
Summary: A novel TME-responsive penetrating nanogel was developed to effectively switch cold tumors to hot, achieving tumor suppression and significantly enhancing anti-tumor immune therapeutics.
ACS APPLIED MATERIALS & INTERFACES
(2021)
Article
Oncology
Mick J. M. van Eijs, Lotte E. van der Wagen, Rogier Mous, Roos J. Leguit, Lisette van de Corput, Anne S. R. van Lindert, Britt B. M. Suelmann, Anna M. Kamphuis, Stefan Nierkens, Karijn P. M. Suijkerbuijk
Summary: Immune checkpoint inhibition (ICI) has shown promise in treating advanced malignancies, but there have been reported cases of hematological neoplasia following ICI for solid tumors. In this study, we present five cases of myeloid malignancies (chronic myeloid leukemia, acute myeloid leukemia, myelodysplastic syndrome, chronic eosinophilic leukemia) in patients treated with anti-PD-1-based therapy. Molecular analyses were performed to identify baseline variants in myeloid genes, and we discuss the potential mechanisms underlying the progression to myeloid malignancies.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2023)
Review
Biochemistry & Molecular Biology
Ivana De Risi, Angela Monica Sciacovelli, Michele Guida
Summary: Immune checkpoint inhibition (ICI) has significantly improved the survival of patients with metastatic melanoma (MM), but it also comes with new and sometimes irreversible toxicities. There is currently no consensus on the optimal duration of ICI therapy, and controlled prospective studies are needed.
Article
Virology
Tatiana Gianni, Valerio Leoni, Mara Sanapo, Federico Parenti, Daniela Bressanin, Catia Barboni, Anna Zaghini, Gabriella Campadelli-Fiume, Andrea Vannini
Summary: The non-attenuated HER2-retargeted oHSV named R-337 showed efficacy against the immunologically hot CT26-HER2 tumor, providing protection and long-term adaptive vaccination effects. The immune protection was based on orchestrating changes in the tumor immune profile, reversing immunosuppression and promoting antitumor responses. The study highlights the importance of characterizing tumor immune markers for more precise application of oncolytic herpesviruses.
Review
Oncology
Nicholas A. Ullman, Paul R. Burchard, Richard F. Dunne, David C. Linehan
Summary: This article summarizes the mechanisms of immunosuppression within the PDAC tumor microenvironment and provides an up-to-date review of completed and ongoing clinical trials using various immunotherapy strategies.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Won Jong Jin, Luke M. Zangl, Meredith Hyun, Elian Massoud, Kaleb Schroeder, Roxana A. Alexandridis, Zachary S. Morris
Summary: Combined radiation and AZD0156 can increase the antitumor response through STING activation. Tumor-derived cell-autonomous IFN-β amplification drives the induction of MHC-I and PD-L1 on the tumor cell surface. Anti-PD-L1 therapy can promote antitumor immune response when combined with RT and AZD0156.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Review
Chemistry, Medicinal
Sanjay Anand, Timothy A. Chan, Tayyaba Hasan, Edward Maytin
Summary: Photodynamic therapy selectively damages tumor cells and vasculature while triggering an anti-tumor immune response. Research on PDT, PTT, and RT occurs in separate silos with minimal interaction between the three topics.
Review
Oncology
Nathan Karin
Summary: By using specific chemokines to enhance anti-tumor immunity, it may be possible to transform cold tumors into hot tumors, thus extending the success of immunotherapy.
